The Syneos Health Podcast: Early Signals
What are the signals today that will define the future of oncology treatment tomorrow?
The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations reshaping drug development in oncology. Hosted by experts across Syneos Health, including Wael Harb, MD, Head of Research and Development and Scientific Strategy in oncology, each episode captures candid conversations about emerging science, evolving market dynamics and the trends poised to influence the future of patient care.
Tune in for timely perspectives on what's next—and what it means for the oncology industry, its stakeholders and most importantly its patients.
Subscribe to The Syneos Health Podcast: Early Signals for new episodes.
If there’s a topic you’d like us to explore, send us a message at podcasts@syneoshealth.com.
For more actionable, future-focused life sciences insights, visit the Syneos Health Insights Hub.
Episodes
11 episodes
Early Signals at ASCO 2026 | AI, Multimodal Data and the Next Era of Precision Oncology
What if artificial intelligence could help remove the uncertainty from cancer treatment decisions?Precision oncology has already transformed cancer care by matching therapies to actionable biomarkers, but today's advances are movi...
Early Signals at ASCO 2026 | Can AI Finally Rebuild Clinical Research?
Less than 5% of patients participate in clinical trials today; a statistic that has remained virtually unchanged for more than two decades despite massive advances in science and technology.In this episode of Early Signals, Dr. Wael Harb...
Early Signals at ASCO 2026 | How Do You Turn Next-Generation ADC Science Into Global Clinical Success?
Antibody-drug conjugates (ADCs) are transforming oncology, but scientific innovation alone isn't enough. As platforms become more sophisticated—with novel linker technologies, diversified payloads and increasingly targeted approaches—the challe...
Early Signals at ASCO 2026 | Reigniting Response: How Oncolytic Viruses May Reshape Ovarian Cancer Treatment
What happens when an established treatment regains its effectiveness against resistant disease?In this episode of the Syneos Health Podcast: Early Signals, Wael Harb, MD, Head of R&D an...
Early Signals at ASCO 2026 | Creating a New Therapeutic Class: The Promise of Direct MYC Inhibition
Can MYC finally be drugged? Learn how MycRx is advancing a direct MYC inhibitor and navigating the science and business of oncology innovation.What if one of cancer's most important drivers was no longer considered "undruggable"...
Welcome to Early Signals!
What are the signals today that will define the future of oncology treatment tomorrow?The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations resha...
Project Optimus Series | Clinical Pharmacology and Project Optimus
We continue our Project Optimus series with a focus on clinical pharmacology—a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb
Project Optimus Series | The Role of Biostatistics
As regulatory expectations evolve under the FDA’s Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach...
Project Optimus Series | Operationalizing Dose Optimization
In this episode, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we now turn to the operational cha...
Project Optimus Series | The Regulatory Implications of Project Optimus
In this episode, Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimus and its profound implications for oncol...
Project Optimus Series | Navigating the Realities of Project Optimus
Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies. While the FDA's hope wa...